NCT07098780 Role of Tranexamic Acid in Reducing Hemorrhagic Events in Bariatric Surgery
| NCT ID | NCT07098780 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Patel Hospital, Pakistan |
| Condition | Hemorrhage |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2023-06-12 |
| Primary Completion | 2025-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 140 participants in total. It began in 2023-06-12 with a primary completion date of 2025-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if tranexamic acid (TXA) helps reduce bleeding during bariatric surgery, such as laparoscopic sleeve gastrectomy (LSG) and mini gastric bypass (MGB). It will also look at how safe TXA is for people undergoing these procedures. The main questions it aims to answer are: Does TXA reduce the amount of blood loss during bariatric surgery? Are there any side effects or complications in patients who receive TXA? Researchers will compare TXA to standard care (no TXA) to see if it is effective in reducing bleeding. Participants will: Receive either TXA or no TXA (placebo) before surgery Undergo standard bariatric surgery (LSG or MGB) Have their blood loss, hemoglobin levels, and any complications monitored during and after surgery
Eligibility Criteria
Inclusion Criteria: * Patients above 18 years of age AND * Undergoing Laparoscopic Sleeve Gastrectomy and MGB * Morbid obesity Exclusion Criteria: * Patients on anti-platelets/anti-coagulants * Patients with inherited or acquired bleeding disorders * Patients with any acute medical condition predisposing to bleeding * Hormonal contraceptives * Known Allery to TXA * Female hormonal replacement therapy
Contact & Investigator
Ghulam Murtaza, MBBS, FCPS, MRCS, MSc (epi)
STUDY DIRECTOR
Patel Hospital
Frequently Asked Questions
Who can join the NCT07098780 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Hemorrhage. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07098780 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07098780 currently recruiting?
Yes, NCT07098780 is actively recruiting participants. Contact the research team at yusra.j.khan@gmail.com for enrollment information.
Where is the NCT07098780 trial being conducted?
This trial is being conducted at Karachi, Pakistan.
Who is sponsoring the NCT07098780 clinical trial?
NCT07098780 is sponsored by Patel Hospital, Pakistan. The principal investigator is Ghulam Murtaza, MBBS, FCPS, MRCS, MSc (epi) at Patel Hospital. The trial plans to enroll 140 participants.